Major depressive disorder with active suicidal ideation is one of the most urgent presentations in outpatient psychiatry, and for a long time the available treatment options were largely the same as those used for depression broadly. SPRAVATO® (esketamine nasal spray) holds a separate FDA approval specifically for this indication, distinct from its approval for treatment-resistant depression, and that distinction carries specific clinical meaning. For patients and families in the Corvallis and Willamette Valley area who are trying to understand what that approval means and whether SPRAVATO® may be relevant, this post covers what the research shows, how treatment works, and where to begin.
If you or someone you know is experiencing thoughts of suicide or self-harm right now, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.
Understanding the SPRAVATO® MDSI Indication and Why Speed Matters
Major depressive disorder (MDD) is a clinical condition characterized by persistent depressed mood, loss of interest or pleasure in activities, changes in sleep and appetite, fatigue, and difficulty concentrating, among other symptoms (Mayo Clinic). Major depressive disorder with active suicidal ideation, abbreviated MDSI, refers to MDD presentations in which the patient is experiencing active thoughts of suicide. This is a clinically distinct context from depression without suicidal ideation, and it calls for both urgency and precision in treatment.
The FDA approved SPRAVATO® for adults with MDD and active suicidal ideation as a separate indication from its approval for treatment-resistant depression (U.S. Food and Drug Administration). Both approvals involve SPRAVATO® administered in a certified, supervised setting, but the patient populations and the clinical problems they address are different. The MDSI approval means that a patient does not necessarily need to have gone through multiple antidepressant trials to be considered for SPRAVATO® under this indication. The presence of MDD with active suicidal ideation is itself the qualifying clinical picture.
One characteristic of SPRAVATO® that is particularly relevant to MDSI presentations is the speed at which it may begin to affect depressive symptoms. Traditional antidepressants typically require weeks to produce meaningful change, which is a significant limitation when a patient is experiencing active suicidal ideation. Research from the National Institute of Mental Health supports ketamine-class compounds, including esketamine, as rapid-acting treatments for depression, with some patients experiencing effects within hours rather than weeks (National Institute of Mental Health, 2024). That potential speed of onset is part of what makes SPRAVATO® clinically relevant to patients where waiting weeks for a new medication to take effect is not a viable approach. This does not mean SPRAVATO® produces immediate or guaranteed relief, and results vary by individual.
SPRAVATO® Treatment for MDD with Suicidal Ideation in Corvallis
Important Limitations to Understand
SPRAVATO® has not been proven to prevent suicide or to directly reduce suicidal thoughts or actions. The FDA’s approval for MDSI is based on its demonstrated effect on depressive symptoms in this patient population, not on evidence that it prevents suicidal acts or ideation. Not all patients respond, and results vary by individual.
SPRAVATO® is also not a substitute for hospitalization. If a treating provider determines that a patient needs inpatient psychiatric care, that clinical determination takes priority. An apparent improvement in symptoms after the first SPRAVATO® dose does not change whether hospitalization is clinically indicated. These limitations are part of what our providers discuss directly with every patient and family considering SPRAVATO® for this indication.
What SPRAVATO® Treatment Looks Like at Catalyst Psychiatry
Treatment at our Corvallis office follows the same supervised model for the MDSI indication as for other SPRAVATO® indications. Your first appointment is a consultation: we review your medical and psychiatric history, conduct our own clinical assessment, verify your insurance, and determine whether SPRAVATO® may be appropriate for your specific situation. If it is recommended, we build a treatment plan with you and enroll you in the SPRAVATO® REMS Program (Risk Evaluation and Mitigation Strategy, the FDA-required safety protocol for this medication) before any sessions are scheduled.
Each treatment session takes place at our office. SPRAVATO® is self-administered as a nasal spray under the direct observation of our clinical team. You remain at the clinic for a mandatory monitoring period of at least two hours after each dose. Blood pressure is checked before each session and monitored throughout. Temporary effects during the monitoring window can include dissociation (a feeling of detachment from thoughts, feelings, or surroundings), dizziness, nausea, and sedation. These effects are temporary and typically resolve within the observation period. You cannot drive on the day of a SPRAVATO® session.
For Family Members and Caregivers
Families and caregivers of patients with MDD and suicidal ideation often reach this information before or alongside the patient. SPRAVATO® requires the patient’s own active participation: clinical assessment, informed consent, and self-administration during each session. Family members cannot initiate or authorize treatment on a patient’s behalf. What family members can do is support the patient in scheduling a consultation, help with transportation logistics, and communicate with our clinical team with the patient’s permission.
If your concern is urgent — meaning you believe someone is in immediate danger — the right response is to call 988 or go to your nearest emergency room. A future appointment at Catalyst Psychiatry is not the appropriate first step when someone is in crisis today. Once a patient is stable and working with us on a longer-term treatment plan, we take coordination with families seriously.
Insurance and Access
SPRAVATO® is covered by most major insurance plans for approved indications, and we verify coverage during your consultation appointment before any treatment is recommended. We are in-network with Providence, Pacific Source, First Choice Health, TriCare, Moda, Compsych, Samaritan Choice, Optum, UHC Commercial, United Behavioral Health, Triwest, and Regence Blue Cross Blue Shield. At this time, we are not accepting Medicare, Medicare Advantage plans, or Oregon Health Plan for SPRAVATO® treatment. For patients with questions about cost, the SPRAVATO® With Me patient support program includes financial assistance resources for eligible patients.
Frequently Asked Questions About SPRAVATO® for MDD with Suicidal Ideation
What is the difference between the SPRAVATO® approval for treatment-resistant depression and the approval for MDD with suicidal ideation?
SPRAVATO® holds two separate FDA approvals. One is for adults with treatment-resistant depression, meaning depression that has not responded adequately to two or more antidepressant trials. The other is for adults with major depressive disorder and active suicidal ideation, regardless of prior antidepressant history. The clinical criteria, patient population, and rationale are distinct for each indication. Our providers determine which, if either, applies to a specific patient’s situation during the consultation.
Does SPRAVATO® prevent suicide?
No. SPRAVATO® is not approved or proven to prevent suicide or to directly reduce suicidal thoughts or actions. Its approval for MDSI is based on clinical evidence that it reduces depressive symptoms in adults with MDD and active suicidal ideation. If you or someone you know is in immediate danger, please call or text 988 or go to your nearest emergency room.
Can SPRAVATO® replace hospitalization?
No. SPRAVATO® is not a substitute for inpatient psychiatric care when a provider determines that hospitalization is clinically necessary. That determination is made by a licensed provider based on a full clinical assessment and takes priority over any treatment that may produce short-term symptom improvement.
What is the difference between SPRAVATO® for treatment-resistant depression versus for MDD with suicidal ideation?
The two indications reflect different patient populations and clinical needs. The treatment-resistant depression indication requires a documented history of inadequate response to multiple antidepressants. The MDSI indication does not require that same prior trial history — the active suicidal ideation in the context of MDD is the qualifying clinical picture. A consultation is where these distinctions are applied to a specific patient’s situation.
How do I find out if SPRAVATO® is appropriate for this indication?
The candidacy evaluation takes place during a consultation at Catalyst Psychiatry. We review the patient’s full medical and psychiatric history, conduct our own assessment, and discuss whether SPRAVATO® may be appropriate given their specific situation. Results vary by individual, and not every patient with MDD and suicidal ideation is a candidate. A consultation is where that question gets a direct, honest answer.
Key Takeaways
- SPRAVATO® holds a separate FDA approval specifically for adults with major depressive disorder and active suicidal ideation, distinct from its approval for treatment-resistant depression.
- SPRAVATO® has not been proven to prevent suicide or directly reduce suicidal thoughts; its approval for MDSI is based on its effect on depressive symptoms in this patient population.
- SPRAVATO® is not a substitute for hospitalization; if a provider determines inpatient care is needed, that clinical judgment takes priority regardless of any symptom improvement.
- Treatment follows the same supervised model used for other SPRAVATO® indications: sessions at our Corvallis office, self-administered under clinical observation, with a mandatory monitoring period of at least two hours.
- Results vary by individual; if you or someone you know is in immediate crisis, please call or text 988 or go to your nearest emergency room.
For patients and families in the Corvallis and Willamette Valley area working through a presentation of MDD with suicidal ideation, SPRAVATO® is a treatment option worth understanding fully, including its limitations. The first step is a consultation at Catalyst Psychiatry, where we evaluate whether SPRAVATO® may be clinically appropriate and discuss what treatment would involve. Call us at 541-730-4400 or reach out through our website when you are ready to have that conversation. If you are in crisis right now, please call or text 988 or go to your nearest emergency room.
References
National Institute of Mental Health. New hope for rapid-acting depression treatment. (2024). https://www.nimh.nih.gov/…
Mayo Clinic. Depression (major depressive disorder): Symptoms and causes. https://www.mayoclinic.org/…
Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. SPRAVATO® treatment should only be pursued under the supervision of a licensed psychiatric provider familiar with your full medical and psychiatric history. Individual results vary, and not all patients respond to SPRAVATO®. SPRAVATO® is not approved to prevent suicide or reduce suicidal ideation, and it is not a substitute for hospitalization when a provider determines inpatient care is necessary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room.